ACTIVE_NOT_RECRUITING

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A Randomized, Multicenter, Double-Masked, Saline-Controlled Trial to Evaluate Corneal Endothelial Cell Density in Subjects With Dry Eye Disease Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months

Official Title

Quick Facts

Study Start:2024-07-31

Study Completion:2025-11

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT06565650

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Be at least 18 years of age at the time of consent. 2. Have a self-reported history of DED in both eyes (OU) for at least 6 months prior to Visit 1 (Screening/Baseline) 3. Have a total corneal fluorescein staining score (tCFS) score \>2 in both eyes 4. Have an Ocular Surface Disease Index (OSDI) score \>17 5. Have a baseline ECD ≥1750 cells/mm2 in each eye 6. Provide written informed consent 7. Be able and willing to follow instructions, including participation in all trial assessments and visits 8. If a contact lens wearer, be willing to discontinue contact lens use during and for 30 minutes following instillation of investigational drug and during study visits	1. Be at least 18 years of age at the time of consent. 2. Have a self-reported history of DED in both eyes (OU) for at least 6 months prior to Visit 1 (Screening/Baseline) 3. Have a total corneal fluorescein staining score (tCFS) score \>2 in both eyes 4. Have an Ocular Surface Disease Index (OSDI) score \>17 5. Have a baseline ECD ≥1750 cells/mm2 in each eye 6. Provide written informed consent 7. Be able and willing to follow instructions, including participation in all trial assessments and visits 8. If a contact lens wearer, be willing to discontinue contact lens use during and for 30 minutes following instillation of investigational drug and during study visits 9. Have any clinically significant ocular surface slit lamp findings and/or in the opinion of the Investigator have any findings that may interfere with trial parameters in either eye 10. Have an ocular or periocular malignancy in either eye 11. Have a history of herpetic keratitis in either eye 12. Have any planned ocular and/or lid surgeries in either eye during the course of the study 13. Have a known allergy and/or sensitivity to the IP 14. Have a history of ocular laser surgery in either eye within 3 months (90 days) prior to Visit 1 (Screening/Baseline) 15. Have a history of incisional ocular surgery or severe trauma in either eye within 3 months (90 days) prior to Visit 1 (Screening/Baseline) 16. Have high contrast best-corrected visual acuity equal to or worse than logMAR +0.7 (Snellen equivalent score of 20/100 or worse) as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) scale in either eye, obtained under bright room lighting 17. Be a woman who is pregnant, nursing or planning a pregnancy during the course of the study 18. Be a woman of childbearing potential who is unwilling to submit to a urine pregnancy test. Non-childbearing potential is defined as a woman who is permanently sterilized (eg, has had a hysterectomy or bilateral tubal ligation or bilateral oophorectomy) or is postmenopausal (without menses for 12 consecutive months). 19. Be a woman of childbearing potential who is not using an acceptable method of birth control. Acceptable methods of contraception include hormonal - oral, implantable, injectable, or transdermal - contraceptives; mechanical contraception - spermicide in conjunction with a barrier such as a diaphragm or condom; intrauterine device; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, the subject must agree to use adequate birth control as defined above for the remainder of the study if she becomes sexually active during the trial. 20. Be currently enrolled in an investigational drug or device trial or plan to enroll during the course of the study 21. Have a condition or be in a situation that the Investigator believes may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Inclusion Criteria

Exclusion Criteria

1. Be at least 18 years of age at the time of consent.
2. Have a self-reported history of DED in both eyes (OU) for at least 6 months prior to Visit 1 (Screening/Baseline)
3. Have a total corneal fluorescein staining score (tCFS) score \>2 in both eyes
4. Have an Ocular Surface Disease Index (OSDI) score \>17
5. Have a baseline ECD ≥1750 cells/mm2 in each eye
6. Provide written informed consent
7. Be able and willing to follow instructions, including participation in all trial assessments and visits
8. If a contact lens wearer, be willing to discontinue contact lens use during and for 30 minutes following instillation of investigational drug and during study visits

1. Be at least 18 years of age at the time of consent.
2. Have a self-reported history of DED in both eyes (OU) for at least 6 months prior to Visit 1 (Screening/Baseline)
3. Have a total corneal fluorescein staining score (tCFS) score \>2 in both eyes
4. Have an Ocular Surface Disease Index (OSDI) score \>17
5. Have a baseline ECD ≥1750 cells/mm2 in each eye
6. Provide written informed consent
7. Be able and willing to follow instructions, including participation in all trial assessments and visits
8. If a contact lens wearer, be willing to discontinue contact lens use during and for 30 minutes following instillation of investigational drug and during study visits
9. Have any clinically significant ocular surface slit lamp findings and/or in the opinion of the Investigator have any findings that may interfere with trial parameters in either eye
10. Have an ocular or periocular malignancy in either eye
11. Have a history of herpetic keratitis in either eye
12. Have any planned ocular and/or lid surgeries in either eye during the course of the study
13. Have a known allergy and/or sensitivity to the IP
14. Have a history of ocular laser surgery in either eye within 3 months (90 days) prior to Visit 1 (Screening/Baseline)
15. Have a history of incisional ocular surgery or severe trauma in either eye within 3 months (90 days) prior to Visit 1 (Screening/Baseline)
16. Have high contrast best-corrected visual acuity equal to or worse than logMAR +0.7 (Snellen equivalent score of 20/100 or worse) as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) scale in either eye, obtained under bright room lighting
17. Be a woman who is pregnant, nursing or planning a pregnancy during the course of the study
18. Be a woman of childbearing potential who is unwilling to submit to a urine pregnancy test. Non-childbearing potential is defined as a woman who is permanently sterilized (eg, has had a hysterectomy or bilateral tubal ligation or bilateral oophorectomy) or is postmenopausal (without menses for 12 consecutive months).
19. Be a woman of childbearing potential who is not using an acceptable method of birth control. Acceptable methods of contraception include hormonal - oral, implantable, injectable, or transdermal - contraceptives; mechanical contraception - spermicide in conjunction with a barrier such as a diaphragm or condom; intrauterine device; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, the subject must agree to use adequate birth control as defined above for the remainder of the study if she becomes sexually active during the trial.
20. Be currently enrolled in an investigational drug or device trial or plan to enroll during the course of the study
21. Have a condition or be in a situation that the Investigator believes may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Contacts and Locations

Study Locations (Sites)

Site 101

Glendale, California, 91204

United States

Site 112

Murrieta, California, 92562

United States

Site 102

Newport Beach, California, 92663

United States

Site 109

Rancho Cordova, California, 95670

United States

Site 106

Torrance, California, 90505

United States

Site 113

Delray Beach, Florida, 33484

United States

Site 107

Morrow, Georgia, 30260

United States

Site 105

Carmel, Indiana, 46290

United States

Site 110

Kansas City, Missouri, 64111

United States

Site 104

Saint Louis, Missouri, 63131

United States

Site 108

Asheville, North Carolina, 28803

United States

Site 103

Memphis, Tennessee, 38119

United States

Collaborators and Investigators

Sponsor: Bausch & Lomb Incorporated

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-31

Study Completion Date2025-11

Study Record Updates

Study Start Date2024-07-31

Study Completion Date2025-11

Terms related to this study

Additional Relevant MeSH Terms

Dry Eye